Expert Interview
A Second Look: Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Ticker(s): REGN, SNY- Rheumatologist in New York
- Manages 8,000 patients with chronic inflammatory disorders
- Highly familiar with the findings of the A3921133 trial of Xeljanz
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
